Skip to content

CONTRIBUTORS

Evan McCulloch, CFA

Portfolio Manager
Franklin Equity Group
United States

In 2023, the biotechnology and pharmaceutical industries began to stabilize, despite continuing to face business and economic challenges that started in 2022. The uptick in merger and acquisition (M&A) activity could act as a tailwind as capital constraints put pressure on smaller or early-stage companies and intensifying drug reimbursement pressures and patent losses impact larger commercial enterprises. We anticipate an industry consolidation-driven inflection point resulting from these pressures. These and other market volatility factors hold the potential to increase the cost required to develop new products and could have significant implications for commercial and portfolio strategies going forward.

The COVID-19 pandemic brought an unprecedented amount of emerging biotechnology to the initial public offering (IPO) stage, but 2023 told a different story that could continue to unfold in 2024. Investors remain cautious in what could be the slowest year for biotech IPOs since 2018. In conjunction with the March 10 collapse of Silicon Valley Bank and already-depressed private equity and venture capital funding, biotech remains in a rough patch as investors are holding out for more proof-of-concept and clinical trial results. We believe these capital constraints are leading small and start-up companies to seek funding and growth opportunities through other avenues, such as M&A activity with larger firms.

Simultaneously, big drugmakers want to deepen their product pipelines as the approaching “patent cliff” and the Inflation Reduction Act (IRA) threaten future revenue, with an estimated US$200 billion in annual patent-related revenue at risk through 2030.1 The Medicare Drug Price Negotiation Program2  embedded in IRA legislation could cause a big drop in the prices at which drugs are reimbursed, creating a “functional” patent expiration. These dynamics are increasingly driving the large pharma companies’ ambitions to fill the looming revenue holes through bolt-on acquisitions of late-stage drug developers and commercial biotechs.

M&A activity across the sector began increasing in 2023 (Exhibit 1) as industry leaders Pfizer and Amgen—both anticipating loss of exclusivity for several key drugs—sought acquisition opportunities during the year. However, the firm hand of regulators was felt during these large acquisitions as the Federal Trade Commission (FTC) initially blocked Amgen’s acquisition of Horizon Therapeutics. Though it was ultimately resolved and the deal closed in October,3 we recognize the regulatory pressures and uncertainty the sector continues to face. To avoid regulatory scrutiny, we may see a shift away from blockbuster (US$10 billion+) deals involving larger commercial-stage targets with meaningful product sales in favor of smaller but later-stage, clinically de-risked names.

Exhibit 1: Reinvigoration of M&A Activity within Biotech

2018–2023 

Source: BioPharma Dive Biotech M&A Tracker, as of 30 November 2023. Deals represented have a minimum of US$50 million of upfront payment.

The road ahead for biotechnology and pharmaceuticals may be different from that of prior years, but as we move into the post-pandemic era, the industry is not lacking innovation prospects despite potential consolidation. We are enthusiastic about progress in the areas of radiopharmaceuticals and antibody drug conjugates (ADCs), which were highlighted by Pfizer’s acquisition of Seagen4 and its ADC expertise, and Eli Lilly’s acquisition of POINT Biopharma5 and its radiopharmaceutical focus. We also see how further progress in the fields of cell therapy, gene therapy and gene editing can allow the industry to address diseases in areas of significant unmet medical need. GLP-1s and weight loss treatments are another area of interest as the fervor around these drugs rapidly expanded the market in 2023. Lastly, we see the potential for the application of artificial intelligence in the drug discovery process to shorten drug development times and, hopefully, improve probabilities of success.

Endnotes

  1. Source: Gardner, Jonathan. “Big Pharma’s Looming Threat: A Patent Cliff of ‘Tectonic Magnitude.’” BioPharma Dive. February 21, 2023.
  2. The Negotiation Program, central to achieving the IRA's goal of lowering drug costs, gives the federal government the ability to negotiate drug prices for certain high-expenditure Medicare Part D drugs, and eventually Part B drugs.
  3. Source: “Amgen Completes Acquisition of Horizon Therapeutics Plc.” Amgen. 2023.
  4. Source: “Pfizer Invests $43 Billion to Battle Cancer”. Pfizer Press Release, 2023.
  5. Source: “Lilly to Acquire POINT BIOPHARMA to Expand Oncology Capabilities into Next-Generation Radioligand Therapies.” POINT Biopharma, 2023.

 

WHAT ARE THE RISKS?

All investments involve risks, including possible loss of principal.

Equity securities are subject to price fluctuation and possible loss of principal.

Investment strategies that incorporate the identification of thematic investment opportunities, and their performance, may be negatively impacted if the investment manager does not correctly identify such opportunities or if the theme develops in an unexpected manner.

Investments in fast-growing industries like the technology and health care sectors (which have historically been volatile) could result in increased price fluctuation, especially over the short term, due to the rapid pace of product change and development and changes in government regulation of companies emphasizing scientific or technological advancement or regulatory approval for new drugs and medical instruments.

To the extent the portfolio invests in a concentration of certain securities, regions or industries, it is subject to increased volatility.

Any companies and/or case studies referenced herein are used solely for illustrative purposes; any investment may or may not be currently held by any portfolio advised by Franklin Templeton. The information provided is not a recommendation or individual investment advice for any particular security, strategy, or investment product and is not an indication of the trading intent of any Franklin Templeton managed portfolio.

IMPORTANT LEGAL INFORMATION

This material is intended to be of general interest only and should not be construed as individual investment advice or a recommendation or solicitation to buy, sell or hold any security or to adopt any investment strategy. It does not constitute legal or tax advice. This material may not be reproduced, distributed or published without prior written permission from Franklin Templeton.

The views expressed are those of the investment manager and the comments, opinions and analyses are rendered as at publication date and may change without notice. The underlying assumptions and these views are subject to change based on market and other conditions and may differ from other portfolio managers or of the firm as a whole. The information provided in this material is not intended as a complete analysis of every material fact regarding any country, region or market. There is no assurance that any prediction, projection or forecast on the economy, stock market, bond market or the economic trends of the markets will be realized. The value of investments and the income from them can go down as well as up and you may not get back the full amount that you invested. Past performance is not necessarily indicative nor a guarantee of future performance. All investments involve risks, including possible loss of principal.

Any research and analysis contained in this material has been procured by Franklin Templeton for its own purposes and may be acted upon in that connection and, as such, is provided to you incidentally. Data from third party sources may have been used in the preparation of this material and Franklin Templeton ("FT") has not independently verified, validated or audited such data.  Although information has been obtained from sources that Franklin Templeton believes to be reliable, no guarantee can be given as to its accuracy and such information may be incomplete or condensed and may be subject to change at any time without notice. The mention of any individual securities should neither constitute nor be construed as a recommendation to purchase, hold or sell any securities, and the information provided regarding such individual securities (if any) is not a sufficient basis upon which to make an investment decision. FT accepts no liability whatsoever for any loss arising from use of this information and reliance upon the comments, opinions and analyses in the material is at the sole discretion of the user.

Franklin Templeton has environmental, social and governance (ESG) capabilities; however, not all strategies or products for a strategy consider “ESG” as part of their investment process.

Products, services and information may not be available in all jurisdictions and are offered outside the U.S. by other FT affiliates and/or their distributors as local laws and regulation permits. Please consult your own financial professional or Franklin Templeton institutional contact for further information on availability of products and services in your jurisdiction.

Issued in the U.S. by Franklin Templeton, One Franklin Parkway, San Mateo, California 94403-1906, (800) DIAL BEN/342-5236, franklintempleton.com. Investments are not FDIC insured; may lose value; and are not bank guaranteed.

You need Adobe Acrobat Reader to view and print PDF documents. Download a free version from Adobe's website.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.